ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Approves Rare Pediatric Disease Designations for WP1066
December 18, 2020Moleculin Biotech announced the US Food and Drug Administration (FDA) has approved its request for a "Rare Pediatric Disease" designation for its drug candidate WP1066. -
Moleculin Announces Positive Interim Results in Adult Glioblastoma Clinical Trial
October 19, 2020Moleculin Biotech announced additional preliminary data from the Phase 1 clinical trial of its immuno-stimulating STAT3 inhibitor, WP1066, in patients with glioblastoma (GBM).
Pharma Sources Insight January 2025
